• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SAGALIAM ACQUISITION CORP. ANNOUNCES RESIGNATION OF THOMAS W. NEUKRANZ AS CHIEF FINANCIAL OFFICER AND DIRECTOR

    5/11/23 1:01:00 PM ET
    $SAGA
    Blank Checks
    Finance
    Get the next $SAGA alert in real time by email

    New York, NY, May 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that Thomas W. Neukranz, its Chief Financial Officer and member of its Board of Directors had resigned effective May 7, 2023. There were no disagreements between the Company and Mr. Neukranz on any matter related to the Company's operations, financial reporting, policies or practices.

    About Sagaliam Acquisition Corp.

    We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. Sagaliam intends to continue to pursue the consummation of a business combination with an appropriate target.

    Non-Solicitation

    This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities shall not constitute an offer to sell or a solicitation of an offer to buy the securities of the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    CONTACT INFORMATION

    Sagaliam Acquisition Corp.,

    Barry Kostiner, Chief Executive Officer

    1800 Avenue of the Stars, Suite 1475

    Los Angeles, CA 90067

    Tel: (213) 616-0011

    [email protected]



    Get the next $SAGA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SAGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gld Sponsor Member, Llc

    3 - Sagaliam Acquisition Corp (0001855351) (Issuer)

    5/11/23 1:10:06 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical

    BAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C. In addition, this new product will be available in both pill and lozenge form providing convenience and a more effective delivery for the users. The team has also begun production of a new slimming formula which will be added to the VIRO nutraceuti

    5/1/24 8:30:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ

    New York, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", SAGAR") (the "Company") received a Nasdaq Hearing Withdrawal letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on March 6, 2024. On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive trading days.1 Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 22, 2023 to regain compliance with the Rule. O

    3/7/24 9:35:00 AM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Sagaliam Acquisition Corp.

    25-NSE - Sagaliam Acquisition Corp (0001855351) (Subject)

    4/9/24 10:30:08 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits

    8-K - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/7/24 9:38:34 AM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form 10-Q filed by Sagaliam Acquisition Corp.

    10-Q - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/6/24 9:45:42 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Leadership Updates

    Live Leadership Updates

    View All

    SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER AND APPOINTMENT OF INDEPENDENT DIRECTORS

    New York, NY, July 28, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on July 25, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-Q"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commissio

    7/28/23 5:00:00 PM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES RESIGNATION OF THOMAS W. NEUKRANZ AS CHIEF FINANCIAL OFFICER AND DIRECTOR

    New York, NY, May 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that Thomas W. Neukranz, its Chief Financial Officer and member of its Board of Directors had resigned effective May 7, 2023. There were no disagreements between the Company and Mr. Neukranz on any matter related to the Company's operations, financial reporting, policies or practices. About Sagaliam Acquisition Corp. We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganizati

    5/11/23 1:01:00 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Financials

    Live finance-specific insights

    View All

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

    Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the audited financial statements for December 31, 2022 and 2021. As part of the recently completed sale of the two operating subsidiaries, Virogenetics, Inc. ("VIRO") and Biogenysis, Inc. ("BGEN"), to Sagaliam Acquisition Corp. (NASDAQ:SAGA)("SAGA") post-closing d

    11/20/23 9:10:00 AM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sagaliam Acquisition Corp. (Amendment)

    SC 13G/A - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 1:49:11 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13G filed by Sagaliam Acquisition Corp.

    SC 13G - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 12:16:06 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13D filed by Sagaliam Acquisition Corp.

    SC 13D - Sagaliam Acquisition Corp (0001855351) (Subject)

    5/11/23 1:08:27 PM ET
    $SAGA
    Blank Checks
    Finance